RPL17 and melanoma: Immune checkpoint inhibitors, notably antibodies targeting PD-1 and CTLA4, have revolutionized the treatment strategies for many cancers, especially advanced melanoma, for which, currently, nearly 50% of tumors in patients can either regress or be controlled for long periods, compared to the historical figure of less than 10% (22).